Danish drug maker Novo Nordisk has struck partnerships with 10 Indian artificial intelligence (AI) startups to streamline its ...

Danish drug maker Novo Nordisk produces a GLP-1 Semaglutide, sold under brand names Ozempic and Rybelsus in Type 2 diabetes and Wegovy in obesity, which has been labelled a “weight-loss” wonder drug.

Found Business Banking provides an accessible and easy-to-use platform designed specifically for freelancers and small ...

One trade group has already filed a lawsuit to try to reverse the decision. Meanwhile, a similar fight over Novo Nordisk’s wildly popular drugs Ozempic and Wegovy looms. Semaglutide, the active ...

Davis-based biological controls company Invasive Species Corp., founded by biologics pioneer Pam Marrone, has taken office ...

The Imperial Beach Arts Bureau invites the community and visitors to join in a guided Art Bike Tour, Saturday morning, October 26th, 10 a.m. to 1 p.m. Riders will meet ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Female leaders in the Boston area’s life sciences industry talked about their leadership styles, their career paths and the ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...